Protein A Resin Market - Global Forecast to 2030
商品番号 : SMB-31693
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年8月 |
| ページ数 | 212 |
| 図表数 | 227 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本調査レポートでは、プロテインA樹脂市場を製品、マトリックスタイプ、原料、用途、エンドユーザー、地域別に分析しています。市場成長の原動力となる要因を探り、様々な業界が直面する課題と機会を検証し、市場リーダーや中小企業を含む競争環境の詳細を提示しています。さらに、5つの地域における様々な市場セグメントの収益を推定し、ミクロ市場分析も含まれています。
本レポートは、プロテインA樹脂市場とそのサブセグメントの正確な収益予測を提供することで、市場リーダー企業と新規参入企業を支援します。また、ステークホルダーが競争環境を理解し、事業をより効果的にポジショニングし、適切な市場開拓戦略を策定するのに役立ちます。さらに、主要な推進要因、制約要因、課題、機会など、市場動向に関する洞察も提供します。
世界のプロテインA樹脂市場は、予測期間中に6.5%のCAGRで成長し、2025年の15億米ドルから2030年には20億米ドルに達すると予測されています。
市場の成長は、CDMO（再生医療等製品製造業者）によるアウトソーシングサービスの増加に起因しており、大手企業が先進国市場において複数のバイオ製造拠点の能力を拡大しています。モノクローナル抗体（mAb）のパイプラインは、FDA承認取得率の高さ、二重特異性抗体および抗体薬物複合体（ADC）の新規上市を背景に、世界的に拡大しています。これにより、エンドユーザーの精製ニーズが高まり、プロテインA樹脂市場の拡大が期待されます。
The global protein A resin market is projected to reach USD 2.0 billion by 2030 from USD 1.5 billion in 2025, at a CAGR of 6.5% during the forecast period.
Market growth is attributed to increased outsourced services through CDMOs, with major players expanding multi-plant biomanufacturing capacities across developed markets. The global monoclonal antibody (mAb) pipeline is growing, marked by high FDA approvals and new bispecific and antibody-drug conjugate launches. This has helped boost purification requirements among end users, which is expected to increase the market for protein A resin.
“Based on product, bulk resins held the largest share of the protein A resin market in 2024.”
Based on products, the protein A resin market is divided into bulk resin, pre-packed columns, lab-scale columns, and others. Unlike pre-packed formats, bulk resin is the industry standard for high-volume purification processes in stainless-steel column setups. While it requires in-house packing and validation, bulk resin provides a much lower cost per cycle and per gram of purified monoclonal antibody. It is the preferred choice among end users because of its reusability. Most types can support 50 to over 200 cycles, enabling long-term production runs with minimal resin replacement. This feature directly enhances the economic efficiency and productivity goals of commercial manufacturing. All these factors make bulk resin the favored choice in the end-use industries.
“Based on matrix type, the agarose-based protein A resin segment accounted for the largest share during the forecast period.”
The protein A resin market is categorized by matrix type into agarose-based, glass/silica-based, and organic polymer-based varieties. Among these, agarose-based protein A resins represent the largest market share. They are known for their improved durability, stronger mechanical properties, and higher capacity to absorb metal dopants at suitable pH levels. Recent developments in agarose-based resins include next-generation products such as Praesto CH1 and DurA Cycle A50, which offer better durability, increased binding capacity, and improved compatibility with complex antibody formats like bispecifics and fragments. These new products feature engineered ligands with enhanced alkaline resistance, enabling longer reuse and better cost efficiency.
“Based on applications, the monoclonal antibodies purification segment has acquired the largest share in 2024.”
Based on applications, the protein A resin market is divided into mAb purification, Fc-fusion protein purification, and other applications. mAb purification holds the largest share in the protein A resin market mainly because of its established role in large-scale biopharmaceutical manufacturing. mAbs are the most widely produced category of biologic therapeutics, requiring large amounts of protein A resin for the primary capture steps in downstream processing. Protein A resin is preferred due to its Fc region binding specificity and compliance with regulatory standards for product purity and consistency. Moreover, a significant portion of the installed biomanufacturing capacity across pharmaceutical companies and contract manufacturing organizations is dedicated to mAb production, which naturally increases demand for protein A resin in this segment.
“Based on end users, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share in 2024.”
Pharmaceutical and biopharmaceutical companies account for the major share in the protein A resin market due to their role as the primary manufacturers of therapeutic proteins, particularly monoclonal antibodies (mAbs) and Fc-fusion proteins. These companies operate large-scale production facilities where protein A resin is extensively used in downstream purification processes, requiring significant resin volumes to meet commercial supply needs and regulatory compliance standards. Additionally, in-house manufacturing setups within these organizations prioritize consistent supply chains and quality control, further reinforcing direct procurement of protein A resins rather than relying solely on outsourced partners. This structural reliance on protein A resin for core biologics manufacturing activities positions pharmaceutical and biopharmaceutical companies as the dominant end-user segment in the market.
“North America is expected to hold a significant market share in the protein A resin market throughout the forecast period.”
The protein A resin market includes five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America held a significant market share for protein A resin. Its dominant position is due to increased manufacturing capacity, focusing on commercial-scale and clinical trial supply production. Investment trends show that US federal and state support promotes domestic biomanufacturing for pandemic preparedness and reducing reliance on international supply chains. Small- to mid-sized biotech firms are increasingly partnering with CDMOs. These factors have helped North America secure the largest market share in 2024.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
- By Designation: C-level Executives (35%), Directors (25%), and Others (40%)
- By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and the Middle East & Africa (5%)
The key players profiled in the protein A resin market are Danaher Corporation (US), Repligen Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific (US), Agilent Technologies (US), GenScript (China), Bio-Rad Laboratories, Inc. (US), Orochem Technologies Inc. (US), Kaneka Corporation (Japan), Abcam Plc. (UK), Ecolab (US), and Tosoh Biosciences LLC (Japan).
Research Coverage
The research report analyzes the protein A resin market by product, matrix type, source, application, end user, and region. It explores the factors driving market growth, examines the challenges and opportunities faced by various industries, and presents details on the competitive landscape, including market leaders and small to medium-sized enterprises. Additionally, it estimates the revenue generated by different market segments across five regions and includes a micromarket analysis.
Reasons to Buy the Report
The report will help market leaders and new entrants by providing accurate revenue estimates for the protein A resin market and subsegments. It will assist stakeholders in understanding the competitive landscape, enabling them to position their businesses more effectively and develop suitable go-to-market strategies. Additionally, the report offers insights into market dynamics, including key drivers, restraints, challenges, and opportunities.
This report provides insightful data on the following pointers:
- Market Penetration: In-depth coverage of product portfolios offered by the top players in the protein A resin market.
- Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the protein A resin market.
- Market Development: Insightful data on profitable developing areas.
- Market Diversification: Details about recent developments and advancements in the protein A resin market.
- Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors.
Table of Contents
1 INTRODUCTION 21
1.1 STUDY OBJECTIVES 21
1.2 MARKET DEFINITION 21
1.3 STUDY SCOPE 22
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 22
1.3.2 INCLUSIONS AND EXCLUSIONS 23
1.3.3 YEARS CONSIDERED 23
1.3.4 CURRENCY CONSIDERED 24
1.4 STAKEHOLDERS 24
1.5 SUMMARY OF CHANGES 24
2 RESEARCH METHODOLOGY 25
2.1 RESEARCH DATA 25
2.1.1 SECONDARY RESEARCH 26
2.1.1.1 Key secondary sources 27
2.1.1.2 Key data from secondary sources 28
2.1.1.3 Objectives of secondary research 28
2.1.2 PRIMARY RESEARCH 29
2.1.2.1 Key primary sources 29
2.1.2.2 Key supply and demand-side participants 29
2.1.2.3 Breakdown of primary interviews 30
2.1.2.4 Objectives of primary research 30
2.1.2.5 Key primary insights 31
2.2 MARKET SIZE ESTIMATION 31
2.2.1 BOTTOM-UP APPROACH 32
2.2.1.1 Company revenue estimation 33
2.2.1.2 Customer-based market estimation 33
2.2.1.3 Primary interviews 34
2.2.2 TOP-DOWN APPROACH 34
2.3 GROWTH RATE ASSUMPTIONS 36
2.4 DATA TRIANGULATION 38
2.5 STUDY ASSUMPTIONS 39
2.6 RESEARCH LIMITATIONS 39
2.7 RISK ANALYSIS 39
3 EXECUTIVE SUMMARY 40
4 PREMIUM INSIGHTS 45
4.1 PROTEIN A RESIN MARKET OVERVIEW 45
4.2 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY COUNTRY AND END USER 46
4.3 PROTEIN A RESIN MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
5.2.1 DRIVERS 49
5.2.1.1 Strong monoclonal antibody pipeline to drive demand 49
5.2.1.2 Advent of continuous bioprocessing to drive adoption 49
5.2.1.3 Increased utilization due to expansion of bispecific antibodies 50
5.2.2 RESTRAINTS 50
5.2.2.1 High manufacturing cost and pricing pressure 50
5.2.2.2 Issues associated with scaling up resin production 51
5.2.3 OPPORTUNITIES 51
5.2.3.1 Rising outsourcing to CDMOs 51
5.2.3.2 Innovative therapeutic indications 51
5.2.4 CHALLENGES 52
5.2.4.1 Limited resin reusability and fouling concerns 52
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 52
5.4 PRICING ANALYSIS 52
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 53
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION 54
5.5 VALUE CHAIN ANALYSIS 55
5.5.1 RESEARCH & DEVELOPMENT 56
5.5.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING 56
5.5.3 DISTRIBUTION AND MARKETING & SALES 56
5.5.4 AFTER-SALES SERVICES 56
5.6 SUPPLY CHAIN ANALYSIS 56
5.6.1 PROMINENT COMPANIES 57
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 57
5.6.3 END USERS 57
5.7 ECOSYSTEM ANALYSIS 58
5.8 INVESTMENT & FUNDING SCENARIO 59
5.9 TECHNOLOGY ANALYSIS 60
5.9.1 KEY TECHNOLOGIES 60
5.9.1.1 Recombinant protein A ligand engineering 60
5.9.1.2 Alkaline-stable ligand development 60
5.9.2 COMPLEMENTARY TECHNOLOGIES 60
5.9.2.1 Automated column packing systems 60
5.9.2.2 In-line monitoring and PAT (process analytical technology) tools 61
5.9.3 ADJACENT TECHNOLOGIES 61
5.9.3.1 Continuous chromatography systems 61
5.9.3.2 Affinity membrane technology 61
5.10 PATENT ANALYSIS 62
5.10.1 INNOVATIONS AND PATENT REGISTRATIONS 63
5.11 TRADE ANALYSIS 63
5.11.1 IMPORT DATA FOR HS CODE 3504 63
5.11.2 EXPORT DATA FOR HS CODE 3504 64
5.12 KEY CONFERENCES & EVENTS, 2025–2026 65
5.13 CASE STUDY ANALYSIS 66
5.13.1 CASE STUDY 1: STRATEGIC CAPACITY EXPANSION BY PUROLITE (ECOLAB) TO STRENGTHEN SUPPLY CHAIN RESILIENCE IN PROTEIN A RESIN BUSINESS 66
5.13.2 CASE STUDY 2: PROCESS INNOVATION BY CYTIVA TO ENHANCE REUSE CYCLES IN PROTEIN A RESINS 66
5.13.3 CASE STUDY 3: TOSOH’S SINGLE-USE STRATEGY TO TAP INTO GROWING DEMAND FOR FLEXIBLE BIOPROCESSING 66
5.14 REGULATORY ANALYSIS 67
5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
5.14.2 REGULATORY FRAMEWORK 68
5.14.2.1 North America 68
5.14.2.1.1 US 68
5.14.2.1.2 Canada 69
5.14.2.2 Europe 69
5.14.2.2.1 UK 69
5.14.2.2.2 Germany 69
5.14.2.2.3 France 69
5.14.2.2.4 Italy 70
5.14.2.2.5 Spain 70
5.14.2.3 Asia Pacific 70
5.14.2.3.1 Japan 70
5.14.2.3.2 China 70
5.14.2.3.3 India 71
5.14.2.3.4 Australia 71
5.14.2.4 Latin America 71
5.14.2.4.1 Brazil 71
5.14.2.4.2 Mexico 72
5.14.2.5 Middle East & Africa 72
5.14.2.5.1 UAE 72
5.14.2.5.2 South Africa 72
5.15 PORTER’S FIVE FORCES ANALYSIS 73
5.15.1 THREAT OF NEW ENTRANTS 74
5.15.2 THREAT OF SUBSTITUTES 74
5.15.3 BARGAINING POWER OF SUPPLIERS 74
5.15.4 BARGAINING POWER OF BUYERS 74
5.15.5 INTENSITY OF COMPETITIVE RIVALRY 74
5.16 KEY STAKEHOLDERS & BUYING CRITERIA 75
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 75
5.16.2 BUYING CRITERIA 76
5.17 UNMET NEEDS 77
5.18 IMPACT OF 2025 US TARIFFS—PROTEIN A RESIN MARKET 77
5.18.1 INTRODUCTION 77
5.18.2 KEY TARIFF RATES 78
5.18.3 PRICE IMPACT ANALYSIS 78
5.18.4 IMPACT ON COUNTRIES/REGIONS 78
5.18.4.1 North America 78
5.18.4.1.1 US 78
5.18.4.2 Europe 79
5.18.4.3 Asia Pacific 79
5.18.5 IMPACT ON END-USE INDUSTRIES 79
5.19 IMPACT OF AI/GEN AI ON PROTEIN A RESIN MARKET 79
5.19.1 MARKET POTENTIAL OF AI/GEN AI IN PROTEIN A RESIN APPLICATIONS 79
5.19.2 AI USE CASES 80
5.19.3 KEY COMPANIES IMPLEMENTING AI/GEN AI 80
5.19.4 FUTURE OF AI/GEN AI IN PROTEIN A RESIN ECOSYSTEM 81
6 PROTEIN A RESIN MARKET, BY PRODUCT 82
6.1 INTRODUCTION 83
6.2 BULK RESINS 83
6.2.1 BULK RESINS TO HOLD LARGEST MARKET SHARE 83
6.3 PREPACKED COLUMNS 84
6.3.1 CONSISTENCY AND LOW CROSS-CONTAMINATION RISK TO SUPPORT ADOPTION 84
6.4 LAB-SCALE COLUMNS 85
6.4.1 FLEXIBILITY, LOW SAMPLE CONSUMPTION, AND HIGH THROUGHPUT TO DRIVE USAGE 85
6.5 OTHER PRODUCTS 86
7 PROTEIN A RESIN MARKET, BY SOURCE 88
7.1 INTRODUCTION 89
7.2 RECOMBINANT PROTEIN A 89
7.2.1 COST-EFFICIENCY OF RECOMBINANT PROTEINS TO DRIVE MARKET GROWTH 89
7.3 NATURAL PROTEIN A 90
7.3.1 ADVANTAGES OF RECOMBINANT PROTEIN A TO RESTRICT NATURALLY SOURCED COUNTERPARTS 90
8 PROTEIN A RESIN MARKET, BY MATRIX TYPE 92
8.1 INTRODUCTION 93
8.2 AGAROSE-BASED PROTEIN A 93
8.2.1 AGAROSE-BASED PROTEIN A TO DOMINATE MARKET 93
8.3 GLASS/SILICA-BASED PROTEIN A 94
8.3.1 LOW PH TOLERANCE OF SILICA-BASED RESINS TO LIMIT MARKET GROWTH 94
8.4 ORGANIC POLYMER-BASED PROTEIN A 95
8.4.1 INCREASING POPULARITY OF ORGANIC POLYMERS TO DRIVE MARKET GROWTH 95
9 PROTEIN A RESIN MARKET, BY APPLICATION 97
9.1 INTRODUCTION 98
9.2 MONOCLONAL ANTIBODY PURIFICATION 98
9.2.1 GROWING DEMAND, RAPID EXPANSION OF APPLICATIONS, AND INCREASING APPROVALS TO ENSURE LARGEST SHARE 98
9.3 FC-FUSION PROTEIN PURIFICATION 99
9.3.1 INNOVATION AND PATENTED PUBLICATIONS TO DRIVE MARKET 99
9.4 OTHER APPLICATIONS 100
10 PROTEIN A RESIN MARKET, BY END USER 102
10.1 INTRODUCTION 103
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 103
10.2.1 EXTENSIVE USE IN BIOLOGICAL DRUG PRODUCTION TO ENSURE STRONG DEMAND 103
10.3 CROS & CDMOS 104
10.3.1 EXPANSION OF BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET GROWTH 104
10.4 ACADEMIC & RESEARCH INSTITUTES 105
10.4.1 INCREASING R&D IN DRUG DISCOVERY TO DRIVE USE OF PROTEIN A RESINS 105
10.5 OTHER END USERS 106
11 PROTEIN A RESIN MARKET, BY REGION 108
11.1 INTRODUCTION 109
11.2 NORTH AMERICA 109
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 110
11.2.2 US 113
11.2.2.1 Expansion in biomanufacturing and domestic capacity to drive market 113
11.2.3 CANADA 114
11.2.3.1 Policy-led capacity build and CDMO growth to drive the market 114
11.3 EUROPE 115
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 115
11.3.2 GERMANY 118
11.3.2.1 Increased capital expenditure from manufacturers to drive market 118
11.3.3 UK 119
11.3.3.1 Government policies and public-private partnerships to drive market 119
11.3.4 FRANCE 119
11.3.4.1 CDMO capacity expansion and public programs to drive market growth 119
11.3.5 ITALY 120
11.3.5.1 Increased Cap Ex from major end-user categories to grow the demand for protein A resin 120
11.3.6 SPAIN 121
11.3.6.1 Increased CDMO and CRO likely to grow demand for protein A resin 121
11.3.7 REST OF EUROPE 121
11.4 ASIA PACIFIC 122
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 123
11.4.2 JAPAN 126
11.4.2.1 CDMO capacity expansions, policy backing, and CDMO investment to propel market 126
11.4.3 CHINA 127
11.4.3.1 Robust biopharmaceutical expansion to grow demand 127
11.4.4 INDIA 127
11.4.4.1 Growth of pharma and biotech industries to drive demand for protein A resins 127
11.4.5 AUSTRALIA 128
11.4.5.1 Increasing demand for protein-based therapeutics to drive growth 128
11.4.6 SOUTH KOREA 129
11.4.6.1 Developments in biopharmaceutical sector to drive market growth 129
11.4.7 REST OF ASIA PACIFIC 130
11.5 LATIN AMERICA 131
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 131
11.5.2 BRAZIL 134
11.5.2.1 Biomanufacturing emphasis and public–private partnerships to catalyze demand 134
11.5.3 MEXICO 134
11.5.3.1 Supportive government initiatives to grow demand for protein A resin 134
11.5.4 REST OF LATIN AMERICA 135
11.6 MIDDLE EAST & AFRICA 136
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 136
11.6.2 GCC COUNTRIES 139
11.6.2.1 Favorable government policies to propel market growth 139
11.6.3 REST OF MIDDLE EAST & AFRICA 139
12 COMPETITIVE LANDSCAPE 141
12.1 INTRODUCTION 141
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 141
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PROTEIN A RESIN MARKET 141
12.3 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024 144
12.4 MARKET SHARE ANALYSIS, 2024 144
12.4.1 MARKET RANKING OF KEY PLAYERS, 2024 146
12.5 COMPANY VALUATION & FINANCIAL METRICS 146
12.6 BRAND/PRODUCT COMPARISON 148
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 149
12.7.1 STARS 149
12.7.2 PERVASIVE PLAYERS 149
12.7.3 EMERGING LEADERS 149
12.7.4 PARTICIPANTS 149
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 151
12.7.5.1 Company footprint 151
12.7.5.2 Region footprint 152
12.7.5.3 Product footprint 152
12.7.5.4 Matrix type footprint 153
12.7.5.5 Application footprint 154
12.7.5.6 End-user footprint 154
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 155
12.8.1 PROGRESSIVE COMPANIES 155
12.8.2 RESPONSIVE COMPANIES 155
12.8.3 DYNAMIC COMPANIES 155
12.8.4 STARTING BLOCKS 155
12.8.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024 157
12.8.5.1 Detailed list of key startups/SMEs 157
12.8.5.2 Competitive benchmarking of key startups/SMEs 158
12.9 COMPETITIVE SCENARIO 159
12.9.1 PRODUCT LAUNCHES & APPROVALS 159
12.9.2 DEALS 159
12.9.3 EXPANSIONS 160
13 COMPANY PROFILES 161
13.1 KEY PLAYERS 161
13.1.1 DANAHER 161
13.1.1.1 Business overview 161
13.1.1.2 Products offered 162
13.1.1.3 Recent developments 163
13.1.1.3.1 Product launches 163
13.1.1.3.2 Deals 163
13.1.1.3.3 Expansions 164
13.1.1.4 MnM view 164
13.1.1.4.1 Key strengths 164
13.1.1.4.2 Strategic choices 164
13.1.1.4.3 Weaknesses & competitive threats 164
13.1.2 THERMO FISHER SCIENTIFIC INC. 165
13.1.2.1 Business overview 165
13.1.2.2 Products offered 166
13.1.2.3 Recent developments 167
13.1.2.3.1 Deals 167
13.1.2.3.2 Expansions 167
13.1.2.4 MnM view 167
13.1.2.4.1 Key strengths 167
13.1.2.4.2 Strategic choices 168
13.1.2.4.3 Weaknesses & competitive threats 168
13.1.3 AGILENT TECHNOLOGIES, INC. 169
13.1.3.1 Business overview 169
13.1.3.2 Products offered 170
13.1.3.3 Recent developments 171
13.1.3.3.1 Deals 171
13.1.3.3.2 Expansions 171
13.1.3.4 MnM view 171
13.1.3.4.1 Key strengths 171
13.1.3.4.2 Strategic choices 172
13.1.3.4.3 Weaknesses & competitive threats 172
13.1.4 BIO-RAD LABORATORIES, INC 173
13.1.4.1 Business overview 173
13.1.4.2 Products offered 174
13.1.5 MERCK KGAA 175
13.1.5.1 Business overview 175
13.1.5.2 Products offered 176
13.1.5.3 Recent developments 177
13.1.5.3.1 Expansions 177
13.1.5.3.2 Other developments 178
13.1.6 REPLIGEN CORPORATION 179
13.1.6.1 Business overview 179
13.1.6.2 Products offered 180
13.1.6.3 Recent developments 181
13.1.6.3.1 Deals 181
13.1.6.4 MnM view 181
13.1.6.4.1 Right to win 181
13.1.6.4.2 Strategic choices 181
13.1.6.4.3 Weaknesses and competitive threats 181
13.1.7 TOSOH BIOSCIENCE 182
13.1.7.1 Business overview 182
13.1.7.2 Products offered 183
13.1.7.3 Recent developments 184
13.1.7.3.1 Expansions 184
13.1.8 ECOLAB INC. 185
13.1.8.1 Business overview 185
13.1.8.2 Products offered 186
13.1.8.3 Recent developments 187
13.1.8.3.1 Product launches 187
13.1.8.3.2 Deals 187
13.1.8.3.3 Expansions 187
13.1.8.4 MnM view 188
13.1.8.4.1 Key strengths 188
13.1.8.4.2 Strategic choices 188
13.1.8.4.3 Weaknesses & competitive threats 188
13.1.9 NOVASEP HOLDING 189
13.1.9.1 Business overview 189
13.1.9.2 Products offered 189
13.1.10 AVANTOR, INC. 190
13.1.10.1 Business overview 190
13.1.10.2 Products offered 191
13.1.11 OROCHEM TECHNOLOGIES, INC. 192
13.1.11.1 Business overview 192
13.1.11.2 Products offered 192
13.1.12 KANEKA CORPORATION 193
13.1.12.1 Business overview 193
13.1.12.2 Products offered 194
13.1.13 JSR CORPORATION 195
13.1.13.1 Business overview 195
13.1.13.2 Products offered 196
13.1.14 GENSCRIPT 197
13.1.14.1 Business overview 197
13.1.14.2 Products offered 198
13.2 OTHER PLAYERS 199
13.2.1 BIO-WORKS 199
13.2.2 GENO TECHNOLOGY, INC. 199
13.2.3 PROMEGA CORPORATION 200
13.2.4 SUZHOU NANOMICRO TECHNOLOGY CO., LTD. 200
13.2.5 TRANSGEN BIOTECH CO., LTD 201
13.2.6 RESYN BIOSCIENCES (PTY) LTD 201
13.2.7 BIOTOOLOMICS LTD. 202
13.2.8 CALIBRE SCIENTIFIC (PROTEIN ARK) 202
13.2.9 SUNRESIN NEW MATERIALS CO., LTD. 203
13.2.10 BEAVER 203
14 APPENDIX 204
14.1 DISCUSSION GUIDE 204
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 208
14.3 CUSTOMIZATION OPTIONS 210
14.4 RELATED REPORTS 210
14.5 AUTHOR DETAILS 211
LIST OF TABLES
TABLE 1 PROTEIN A RESIN MARKET: INCLUSIONS & EXCLUSIONS 23
TABLE 2 PROTEIN A RESIN MARKET: STUDY ASSUMPTIONS 39
TABLE 3 PROTEIN A RESIN MARKET: RISK ANALYSIS 39
TABLE 4 PROTEIN A RESIN MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 49
TABLE 5 KEY PARAMETERS IMPACTING PRICES FOR PROTEIN A RESIN 53
TABLE 6 AVERAGE SELLING PRICE TREND OF PROTEIN A RESIN, BY KEY PLAYER,
2022–2024 (USD) 54
TABLE 7 AVERAGE SELLING PRICE TREND OF PROTEIN A RESIN, BY REGION,
2022–2024 (USD) 55
TABLE 8 PROTEIN A RESIN MARKET: ROLE IN ECOSYSTEM 58
TABLE 9 PROTEIN A RESIN MARKET: INNOVATIONS AND PATENT REGISTRATIONS,
2022–2024 63
TABLE 10 IMPORT SCENARIO FOR HS CODE 3504, BY COUNTRY,
2020–2024 (USD THOUSAND) 64
TABLE 11 EXPORT SCENARIO FOR HS CODE 3504, BY COUNTRY,
2020–2024 (USD THOUSAND) 65
TABLE 12 PROTEIN A RESIN: LIST OF KEY CONFERENCES & EVENTS,
JANUARY 2025–DECEMBER 2026 65
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANISATIONS 68
TABLE 18 PROTEIN A RESIN MARKET: PORTER’S FIVE FORCES ANALYSIS 73
TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF PROTEIN A RESIN, BY PRODUCT 75
TABLE 20 KEY BUYING CRITERIA OF PROTEIN A RESIN, BY END USER 76
TABLE 21 PROTEIN A RESIN MARKET: UNMET NEEDS 77
TABLE 22 US ADJUSTED RECIPROCAL TARIFF RATES, 2024 78
TABLE 23 KEY COMPANIES IMPLEMENTING AI/GEN AI IN PROTEIN A RESIN MARKET 80
TABLE 24 PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 83
TABLE 25 PROTEIN A RESIN MARKET FOR BULK RESINS, BY REGION,
2023–2030 (USD MILLION) 84
TABLE 26 PROTEIN A RESIN MARKET FOR PREPACKED COLUMNS, BY REGION,
2023–2030 (USD MILLION) 85
TABLE 27 PROTEIN A RESIN MARKET FOR LAB-SCALE COLUMNS, BY REGION,
2023–2030 (USD MILLION) 86
TABLE 28 PROTEIN A RESIN MARKET FOR OTHER PRODUCTS, BY REGION,
2023–2030 (USD MILLION) 87
TABLE 29 PROTEIN A RESIN MARKET, BY SOURCE, 2023–2030 (USD MILLION) 89
TABLE 30 RECOMBINANT PROTEIN A MARKET, BY REGION, 2023–2030 (USD MILLION) 90
TABLE 31 NATURAL PROTEIN A MARKET, BY REGION, 2023–2030 (USD MILLION) 91
TABLE 32 PROTEIN A RESIN MARKET, BY MATRIX TYPE, 2023–2030 (USD MILLION) 93
TABLE 33 AGAROSE-BASED PROTEIN A MARKET, BY REGION, 2023–2030 (USD MILLION) 94
TABLE 34 GLASS/SILICA-BASED PROTEIN A MARKET, BY REGION,
2023–2030 (USD MILLION) 95
TABLE 35 ORGANIC POLYMER-BASED PROTEIN A MARKET, BY REGION,
2023–2030 (USD MILLION) 96
TABLE 36 PROTEIN A RESIN MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 98
TABLE 37 PROTEIN A RESIN MARKET FOR MAB PURIFICATION, BY REGION,
2023–2030 (USD MILLION) 99
TABLE 38 PROTEIN A RESIN MARKET FOR FC-FUSION PURIFICATION, BY REGION,
2023–2030 (USD MILLION) 100
TABLE 39 PROTEIN A RESIN MARKET FOR OTHER APPLICATIONS, BY REGION,
2023–2030 (USD MILLION) 101
TABLE 40 PROTEIN A RESIN MARKET, BY END USER, 2023–2030 (USD MILLION) 103
TABLE 41 PROTEIN A RESIN MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION) 104
TABLE 42 PROTEIN A RESIN MARKET FOR CROS & CDMOS, BY REGION,
2023–2030 (USD MILLION) 105
TABLE 43 PROTEIN A RESIN MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 106
TABLE 44 PROTEIN A RESIN MARKET FOR OTHER END USERS, BY REGION,
2023–2030 (USD MILLION) 107
TABLE 45 PROTEIN A RESIN MARKET, BY REGION, 2023–2030 (USD MILLION) 109
TABLE 46 NORTH AMERICA: KEY MACROINDICATORS 111
TABLE 47 NORTH AMERICA: PROTEIN A RESIN MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 48 NORTH AMERICA: PROTEIN A RESIN MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 111
TABLE 49 NORTH AMERICA: PROTEIN A RESIN MARKET, BY SOURCE,
2023–2030 (USD MILLION) 112
TABLE 50 NORTH AMERICA: PROTEIN A RESIN MARKET, BY MATRIX TYPE,
2023–2030 (USD MILLION) 112
TABLE 51 NORTH AMERICA: PROTEIN A RESIN MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 112
TABLE 52 NORTH AMERICA: PROTEIN A RESIN MARKET, BY END USER,
2023–2030 (USD MILLION) 113
TABLE 53 US: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 114
TABLE 54 CANADA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 115
TABLE 55 EUROPE: KEY MACROINDICATORS 116
TABLE 56 EUROPE: PROTEIN A RESIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 57 EUROPE: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 116
TABLE 58 EUROPE: PROTEIN A RESIN MARKET, BY SOURCE, 2023–2030 (USD MILLION) 117
TABLE 59 EUROPE: PROTEIN A RESIN MARKET, BY MATRIX TYPE, 2023–2030 (USD MILLION) 117
TABLE 60 EUROPE: PROTEIN A RESIN MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 117
TABLE 61 EUROPE: PROTEIN A RESIN MARKET, BY END USER, 2023–2030 (USD MILLION) 118
TABLE 62 GERMANY: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 118
TABLE 63 UK: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 119
TABLE 64 FRANCE: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 120
TABLE 65 ITALY: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 120
TABLE 66 SPAIN: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 121
TABLE 67 REST OF EUROPE: PROTEIN A RESIN MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 122
TABLE 68 ASIA PACIFIC: KEY MACROINDICATORS 124
TABLE 69 ASIA PACIFIC: PROTEIN A RESIN, BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 70 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 124
TABLE 71 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY SOURCE, 2023–2030 (USD MILLION) 125
TABLE 72 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY MATRIX TYPE,
2023–2030 (USD MILLION) 125
TABLE 73 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 125
TABLE 74 ASIA PACIFIC: PROTEIN A RESIN MARKET, BY END USER,
2023–2030 (USD MILLION) 126
TABLE 75 JAPAN: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 126
TABLE 76 CHINA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 127
TABLE 77 INDIA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 128
TABLE 78 AUSTRALIA: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 129
TABLE 79 SOUTH KOREA: PROTEIN A RESIN MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 130
TABLE 80 REST OF ASIA PACIFIC: PROTEIN A RESIN MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 131
TABLE 81 LATIN AMERICA: KEY MACROINDICATORS 131
TABLE 82 LATIN AMERICA: PROTEIN A RESIN, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 83 LATIN AMERICA: PROTEIN A RESIN MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 132
TABLE 84 LATIN AMERICA: PROTEIN A RESIN MARKET, BY SOURCE,
2023–2030 (USD MILLION) 132
TABLE 85 LATIN AMERICA: PROTEIN A RESIN MARKET, BY MATRIX TYPE,
2023–2030 (USD MILLION) 133
TABLE 86 LATIN AMERICA: PROTEIN A RESIN MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 133
TABLE 87 LATIN AMERICA: PROTEIN A RESIN MARKET, BY END USER,
2023–2030 (USD MILLION) 133
TABLE 88 BRAZIL: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 134
TABLE 89 MEXICO: PROTEIN A RESIN MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 135
TABLE 90 REST OF LATIN AMERICA: PROTEIN A RESIN MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 135
TABLE 91 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 136
TABLE 92 MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY REGION,
2023–2030 (USD MILLION) 137
TABLE 93 MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 137
TABLE 94 MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY SOURCE,
2023–2030 (USD MILLION) 137
TABLE 95 MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY MATRIX TYPE,
2023–2030 (USD MILLION) 138
TABLE 96 MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 138
TABLE 97 MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY END USER,
2023–2030 (USD MILLION) 138
TABLE 98 GCC COUNTRIES: PROTEIN A RESIN MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 139
TABLE 99 REST OF MIDDLE EAST & AFRICA: PROTEIN A RESIN MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 140
TABLE 100 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PROTEIN A RESIN MARKET, 2022–2025 141
TABLE 101 PROTEIN A RESIN MARKET: DEGREE OF COMPETITION 145
TABLE 102 PROTEIN A RESIN MARKET: REGION FOOTPRINT 152
TABLE 103 PROTEIN A RESIN MARKET: PRODUCT FOOTPRINT 152
TABLE 104 PROTEIN A RESIN MARKET: MATRIX TYPE FOOTPRINT 153
TABLE 105 PROTEIN A RESIN MARKET: APPLICATION FOOTPRINT 154
TABLE 106 PROTEIN A RESIN MARKET: END-USER FOOTPRINT 154
TABLE 107 PROTEIN A RESIN MARKET: DETAILED LIST OF KEY STARTUPS/SMES 157
TABLE 108 PROTEIN A RESIN MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT AND REGION 158
TABLE 109 PROTEIN A RESIN MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–JUNE 2025 159
TABLE 110 PROTEIN A RESIN MARKET: DEALS, JANUARY 2022–JUNE 2025 159
TABLE 111 PROTEIN A RESIN MARKET: EXPANSIONS, JANUARY 2021–JUNE 2025 160
TABLE 112 DANAHER: COMPANY OVERVIEW 161
TABLE 113 DANAHER: PRODUCTS OFFERED 162
TABLE 114 DANAHER: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025 163
TABLE 115 DANAHER: DEALS, JANUARY 2022–JULY 2025 163
TABLE 116 DANAHER: EXPANSIONS, JANUARY 2022–JULY 2025 164
TABLE 117 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 165
TABLE 118 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 166
TABLE 119 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JULY 2025 167
TABLE 120 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–JULY 2025 167
TABLE 121 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 169
TABLE 122 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 170
TABLE 123 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–JULY 2025 171
TABLE 124 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022–JULY 2025 171
TABLE 125 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 173
TABLE 126 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 174
TABLE 127 MERCK KGAA: COMPANY OVERVIEW 175
TABLE 128 MERCK KGAA: PRODUCTS OFFERED 176
TABLE 129 MERCK KGAA: EXPANSIONS, JANUARY 2022–JULY 2025 177
TABLE 130 MERCK KGAA: OTHER DEVELOPMENTS, JANUARY 2022–JULY 2025 178
TABLE 131 REPLIGEN CORPORATION: COMPANY OVERVIEW 179
TABLE 132 REPLIGEN CORPORATION: PRODUCTS OFFERED 180
TABLE 133 REPLIGEN CORPORATION: DEALS, JANUARY 2022–JULY 2025 181
TABLE 134 TOSOH BIOSCIENCE: COMPANY OVERVIEW 182
TABLE 135 TOSOH BIOSCIENCE: PRODUCTS OFFERED 183
TABLE 136 TOSOH BIOSCIENCE: EXPANSIONS, JANUARY 2022–JULY 2025 184
TABLE 137 ECOLAB INC.: COMPANY OVERVIEW 185
TABLE 138 ECOLAB INC.: PRODUCTS OFFERED 186
TABLE 139 ECOLAB INC.: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025 187
TABLE 140 ECOLAB INC.: DEALS, JANUARY 2022–JULY 2025 187
TABLE 141 ECOLAB INC.: EXPANSIONS, JANUARY 2022–JULY 2025 187
TABLE 142 NOVOSEP HOLDING: COMPANY OVERVIEW 189
TABLE 143 NOVOSEP HOLDING: PRODUCTS OFFERED 189
TABLE 144 AVANTOR, INC.: COMPANY OVERVIEW 190
TABLE 145 AVANTOR, INC.: PRODUCTS OFFERED 191
TABLE 146 OROCHEM TECHNOLOGIES, INC.: COMPANY OVERVIEW 192
TABLE 147 OROCHEM TECHNOLOGIES, INC.: PRODUCTS OFFERED 192
TABLE 148 KANEKA CORPORATION: COMPANY OVERVIEW 193
TABLE 149 KANEKA CORPORATION: PRODUCTS OFFERED 194
TABLE 150 JSR CORPORATION: COMPANY OVERVIEW 195
TABLE 151 JSR CORPORATION: PRODUCTS OFFERED 196
TABLE 152 GENSCRIPT: COMPANY OVERVIEW 197
TABLE 153 GENSCRIPT: PRODUCTS OFFERED 198
TABLE 154 BIO-WORKS: COMPANY OVERVIEW 199
TABLE 155 GENO TECHNOLOGY, INC.: COMPANY OVERVIEW 199
TABLE 156 PROMEGA CORPORATION: COMPANY OVERVIEW 200
TABLE 157 SUZHOU NANOMICRO TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 200
TABLE 158 TRANSGEN BIOTECH CO., LTD: COMPANY OVERVIEW 201
TABLE 159 RESYN BIOSCIENCES (PTY) LTD: COMPANY OVERVIEW 201
TABLE 160 BIOTOOLOMICS LTD.: COMPANY OVERVIEW 202
TABLE 161 CALIBRE SCIENTIFIC (PROTEIN ARK): COMPANY OVERVIEW 202
TABLE 162 SUNRESIN NEW MATERIALS CO., LTD.: COMPANY OVERVIEW 203
TABLE 163 BEAVER: COMPANY OVERVIEW 203
LIST OF FIGURES
FIGURE 1 PROTEIN A RESIN MARKET SEGMENTATION & REGIONAL SCOPE 22
FIGURE 2 PROTEIN A RESIN MARKET: RESEARCH DATA 25
FIGURE 3 PROTEIN A RESIN MARKET: RESEARCH DESIGN 26
FIGURE 4 PROTEIN A RESIN MARKET: KEY SECONDARY SOURCES 27
FIGURE 5 PROTEIN A RESIN MARKET: KEY DATA FROM SECONDARY SOURCES 28
FIGURE 6 PROTEIN A RESIN MARKET: KEY PRIMARY SOURCES
(DEMAND AND SUPPLY SIDES) 29
FIGURE 7 PROTEIN A RESIN MARKET: KEY SUPPLY AND DEMAND-SIDE PARTICIPANTS 29
FIGURE 8 PROTEIN A RESIN MARKET: BREAKDOWN OF PRIMARY INTERVIEWS (BY COMPANY TYPE, DESIGNATION, AND REGION) 30
FIGURE 9 PROTEIN A RESIN MARKET: KEY INSIGHTS FROM PRIMARY EXPERTS 31
FIGURE 10 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 32
FIGURE 11 PROTEIN A RESIN MARKET: COMPANY REVENUE ESTIMATION 33
FIGURE 12 PROTEIN A RESIN MARKET: END-USER AND REVENUE-MAPPING-BASED MARKET SIZE ESTIMATION METHODOLOGY 34
FIGURE 13 PROTEIN A RESIN MARKET: TOP-DOWN APPROACH 35
FIGURE 14 GROWTH PROJECTIONS ON REVENUE IMPACT OF KEY MACROINDICATORS 36
FIGURE 15 PROTEIN A RESIN MARKET: DATA TRIANGULATION METHODOLOGY 38
FIGURE 16 PROTEIN A RESIN MARKET SHARE, BY PRODUCT, 2025 VS. 2030 40
FIGURE 17 PROTEIN A RESIN MARKET, BY SOURCE, 2025 VS. 2030 (USD MILLION) 41
FIGURE 18 PROTEIN A RESIN MARKET, BY MATRIX TYPE, 2025 VS. 2030 (USD MILLION) 42
FIGURE 19 PROTEIN A RESIN MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 42
FIGURE 20 PROTEIN A RESIN MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 43
FIGURE 21 PROTEIN A RESIN MARKET: GEOGRAPHIC SNAPSHOT (2024) 44
FIGURE 22 RISING ADOPTION OF PREPACKED DISPOSABLE COLUMNS TO FUEL MARKET GROWTH 45
FIGURE 23 CHINA AND JAPAN TO ACQUIRE MAJOR SHARES OF ASIA PACIFIC MARKET IN 2024 46
FIGURE 24 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030 47
FIGURE 25 PROTEIN A RESIN MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
FIGURE 26 PROTEIN A RESIN MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 52
FIGURE 27 AVERAGE SELLING PRICE TREND OF PROTEIN A RESIN,
BY KEY PLAYER, 2022–2024 (USD) 53
FIGURE 28 AVERAGE SELLING PRICE TREND OF PROTEIN A RESIN,
BY REGION, 2022–2024 (USD) 54
FIGURE 29 PROTEIN A RESIN MARKET: VALUE CHAIN ANALYSIS 55
FIGURE 30 PROTEIN A RESIN MARKET: SUPPLY CHAIN ANALYSIS 56
FIGURE 31 PROTEIN A RESIN MARKET: ECOSYSTEM ANALYSIS 58
FIGURE 32 PROTEIN A RESIN MARKET: FUNDING AND NUMBER OF DEALS,
2019–2023 (USD MILLION) 59
FIGURE 33 NUMBER OF DEALS IN PROTEIN A RESIN MARKET, BY KEY PLAYER, 2019–2023 59
FIGURE 34 VALUE OF DEALS IN PROTEIN A RESIN MARKET, BY KEY PLAYER,
2019–2023 (USD) 60
FIGURE 35 PROTEIN A RESIN MARKET: TOP COMPANIES/APPLICANTS FOR PROTEIN A RESIN PATENTS AND NUMBER OF PATENTS GRANTED, 2015–2025 62
FIGURE 36 PROTEIN A RESIN MARKET: IMPORT SCENARIO FOR HS CODE 3504, 2020–2024 63
FIGURE 37 PROTEIN A RESIN MARKET: EXPORT SCENARIO FOR HS CODE 3504, 2020–2024 64
FIGURE 38 PROTEIN A RESIN MARKET: PORTER’S FIVE FORCES ANALYSIS 73
FIGURE 39 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
FOR PROTEIN A RESIN, BY PRODUCT 75
FIGURE 40 KEY BUYING CRITERIA OF PROTEIN A RESIN, BY END USER 76
FIGURE 41 KEY AI USE CASES IN PROTEIN A RESIN MARKET 80
FIGURE 42 NORTH AMERICA: PROTEIN A RESIN MARKET SNAPSHOT (2024) 110
FIGURE 43 ASIA PACIFIC: PROTEIN A RESIN MARKET SNAPSHOT (2024) 123
FIGURE 44 REVENUE ANALYSIS OF KEY PLAYERS IN PROTEIN A RESIN MARKET,
2020–2024 (USD MILLION) 144
FIGURE 45 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PROTEIN A RESIN MARKET, 2024 144
FIGURE 46 MARKET RANKING OF KEY PLAYERS IN PROTEIN A RESIN MARKET, 2024 146
FIGURE 47 EV/EBITDA OF TOP THREE PLAYERS (2025) 146
FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF TOP THREE PLAYERS (2025) 147
FIGURE 49 PROTEIN A RESIN MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 148
FIGURE 50 PROTEIN A RESIN MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 150
FIGURE 51 PROTEIN A RESIN MARKET: COMPANY FOOTPRINT 151
FIGURE 52 PROTEIN A RESIN MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2024 156
FIGURE 53 DANAHER: COMPANY SNAPSHOT 162
FIGURE 54 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 166
FIGURE 55 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 170
FIGURE 56 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 174
FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT (2024) 176
FIGURE 58 REPLIGEN CORPORATION: COMPANY SNAPSHOT (2024) 180
FIGURE 59 TOSOH BIOSCIENCE: COMPANY SNAPSHOT (2024) 183
FIGURE 60 ECOLAB INC.: COMPANY SNAPSHOT (2024) 186
FIGURE 61 AVANTOR, INC.: COMPANY SNAPSHOT (2024) 191
FIGURE 62 KANEKA CORPORATION: COMPANY SNAPSHOT (2024) 193
FIGURE 63 JSR CORPORATION: COMPANY SNAPSHOT (2024) 196
FIGURE 64 GENSCRIPT: COMPANY SNAPSHOT (2024) 198
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11